Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKinsey
Baxter
Mallinckrodt
AstraZeneca

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

ZOSTAVAX Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for ZOSTAVAX

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of Alabama at BirminghamPhase 2
Oregon Health and Science UniversityPhase 2
Merck Sharp & Dohme Corp.Phase 4

See all ZOSTAVAX clinical trials

Recent Litigation for ZOSTAVAX

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CUBIST PHARMACEUTICALS LLC v. CIPLA USA INC.2019-05-24
GILEAD SCIENCES, INC. v. ZYDUS PHARMACEUTICALS (USA) INC.2019-01-15
Onyx Therapeutics, Inc. v. Breckenridge Pharmaceutical, Inc.2019-01-11

See all ZOSTAVAX litigation

PTAB Litigation
PetitionerDate
CSL Behring GmbH2018-12-21
Fresenius Kabi USA, LLC2015-11-02
Momenta Pharmaceuticals, Inc.2015-07-02

See all ZOSTAVAX litigation

Patent Text Search: US Patents for ZOSTAVAX

These patents were identified by searching patent claims

Supplementary Protection Certificates for ZOSTAVAX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
300555 Netherlands   Start Trial PRODUCT NAME: CRM197 EIWIT; REGISTRATION NO/DATE: EU/1/10/614/001 20100315
15C0094 France   Start Trial PRODUCT NAME: OLIGOSIDE DE NEISSERIA MENINGITIDIS DU GROUPE C CONJUGUE A LA PROTEINE CRM-197 DE CORYNEBACTERIUM DIPHTHERIAE,OLIGOSIDE DE NEISSERIA MENINGITIDIS DU GROUPE W135 CONJUGUE A LA PROTEINE CRM-197 DE CORYNEBACTERIUM DIPHTHERIAE,OLIGOSIDE DE NEISSERIA MENINGITIDIS DU GROUPE Y CONJUGUE A LA PROTEINE CRM-197 DE CORYNEBACTERIUM DIPHTHERIAE.; REGISTRATION NO/DATE: EU/1/10/614/001 20100317
CR 2016 00014 Denmark   Start Trial PRODUCT NAME: CARFILZOMIB OG FARMACEUTISK ACCEPTABLE SALTE HERAF; REG. NO/DATE: EU/1/15/1060 20151123
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
AstraZeneca
Moodys
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.